DexCom, Inc. vs Moody's Corporation — how do they compare? DexCom, Inc. trades at $90.33 (market cap $33.79B), while Moody's Corporation trades at $477.07 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 2.4× DexCom, Inc.'s market cap, and Moody's Corporation pays a 0.86% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MCO | |
|---|---|---|
Market Cap | $33.79B | $82.52B |
Sector | Health | Financials |
52-Week High | $89.53 | $539.61 |
52-Week Low | $54.84 | $412.23 |
Enterprise Value | $33.24B | $88.54B |
Dividend Yield | — | 0.86% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Moody's Corporation (MCO) trades at $477.00, down 0.24% on the day, with strong fundamentals including 80.15% ROE and 34.25% net margin. The stock shows bearish technical signals but maintains robust earnings momentum with three consecutive quarterly beats. Revenue growth accelerated to $7.72 billion in 2025, while analyst consensus remains bullish with a $561.88 price target representing 18% upside potential.
MCO presents a compelling growth story with premium valuation metrics (P/E 30.23) justified by consistent earnings outperformance and dominant market position. Key risks include sensitivity to debt issuance cycles and elevated valuation multiples. The combination of strong profitability, analyst support, and dividend payments supports a positive long-term outlook despite near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →